Telisotuzumab vedotin is a monoclonal antibody developed by AbbVie for non-small cell lung cancer. Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan...
4 KB (407 words) - 18:19, 19 April 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
12 KB (1,049 words) - 10:54, 12 January 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
9 KB (1,081 words) - 04:46, 16 June 2022
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
14 KB (1,689 words) - 00:46, 6 December 2023
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
10 KB (661 words) - 04:10, 26 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
17 KB (1,489 words) - 05:47, 7 April 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
31 KB (3,413 words) - 23:30, 21 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
11 KB (934 words) - 06:00, 10 April 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
26 KB (2,542 words) - 19:54, 20 March 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
10 KB (579 words) - 06:46, 26 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
5 KB (412 words) - 23:17, 19 June 2023
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
10 KB (1,131 words) - 19:14, 31 March 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
7 KB (572 words) - 13:08, 12 April 2024
on 11 August 2020. Retrieved 5 October 2020. "Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived from...
135 KB (4,013 words) - 06:50, 25 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
40 KB (4,580 words) - 05:24, 3 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
19 KB (1,435 words) - 22:27, 16 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
34 KB (3,010 words) - 05:48, 22 May 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
23 KB (1,645 words) - 05:49, 26 March 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
15 KB (975 words) - 03:53, 27 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
24 KB (2,053 words) - 21:07, 12 April 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
25 KB (3,123 words) - 20:10, 26 April 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
22 KB (1,692 words) - 06:45, 11 March 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
36 KB (3,929 words) - 14:48, 30 May 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
16 KB (1,784 words) - 04:08, 6 January 2024
ClinicalTrials.gov Clinical trial number NCT01979536 for "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly...
22 KB (1,846 words) - 09:44, 9 May 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
68 KB (5,993 words) - 00:22, 20 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
10 KB (594 words) - 16:12, 1 March 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
45 KB (5,341 words) - 08:28, 10 June 2024
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
10 KB (721 words) - 08:54, 23 December 2023
Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF BNN-20 BNN-27 Cenegermin...
14 KB (1,289 words) - 01:36, 18 May 2024